Halozyme Therapeutics | HALO - Current Assets



Halozyme Therapeutics reported $1.12B in Current Assets for its fiscal quarter ending in June of 2025.


Current Assets Change Date
Acadia Pharmaceuticals USD 960.55M 89.61M Jun/2025
Agios Pharmaceuticals USD 1.02B 50.85M Jun/2025
Alnylam Pharmaceuticals USD 3.64B 375.44M Jun/2025
Amarin USD 573.06M 22.34M Mar/2025
Amgen USD 26.73B 195M Jun/2025
Baxter International USD 7.04B 1.82B Mar/2025
Cytokinetics USD 886.54M 69.51M Jun/2025
DBV Technologies USD 121.24M 92.09M Jun/2025
Eli Lilly USD 49.85B 8.59B Jun/2025
Halozyme Therapeutics USD 1.12B 139.35M Jun/2025
Ionis Pharmaceuticals USD 2.58B 158.22M Jun/2025
MannKind USD 279.03M 5.29M Jun/2025
Pfizer USD 43.7B 2.16B Jun/2025
United Therapeutics USD 3.83B 112.9M Jun/2025